Brightcove to Present at the Needham Virtual Growth Conference

Brightcove to Present at the Needham Virtual Growth Conference

BOSTON–(BUSINESS WIRE)–Brightcove Inc. (NASDAQ: BCOV), the global leader in video for business, today announced that its Chief Executive Officer, Jeff Ray, Chief Financial Officer, Rob Noreck, and Executive Vice President of Corporate Development, Michael Loria, will present at the Needham Virtual Growth Conference.

The Brightcove presentation is scheduled for Wednesday, January 13, 2021 at 8:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the Brightcove investor relations website at http://investor.brightcove.com/index.php/events-presentations. A replay of the webcast will also be available for a limited time.

About Brightcove

When video is done right, it can have a powerful and lasting effect. Hearts open. Minds change. Creativity thrives. Since 2004, Brightcove has been helping customers discover and experience the incredible power of video through its award-winning technology, empowering organizations in more than 70 countries across the globe to touch audiences in bold and innovative ways.

Brightcove achieves this by developing technologies once thought impossible, providing customer support without parallel or excuses, and leveraging the expertise and resources of a global infrastructure. Video is the world’s most compelling, exciting medium. Visit www.brightcove.com for more information. Video That Means Business.™

Investors:

ICR for Brightcove

Brian Denyeau, 646-277-1251

[email protected]

Media:

Brightcove

Meredith Duhaime

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Networks Data Management Audio/Video Technology Software

MEDIA:

Owens & Minor to Present at the 39th Annual J.P. Morgan Healthcare Conference

Owens & Minor to Present at the 39th Annual J.P. Morgan Healthcare Conference

RICHMOND, Va.–(BUSINESS WIRE)–
Owens & Minor, Inc. (NYSE: OMI) announced today that the company will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021.

Ed Pesicka, President and CEO, of Owens & Minor, will make a presentation at the conference at 10:50 AM ET on January 13, 2021 that will be webcast live and may be accessed at www.owens-minor.com under the Investor Relations section. The webcast will be archived and available for replay on the website for 30 days.

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a global healthcare solutions company with integrated technologies, products, and services aligned to deliver significant and sustained value for healthcare providers and manufacturers across the continuum of care. With over 15,000 dedicated teammates serving healthcare industry customers in 70 countries, Owens & Minor helps to reduce total costs across the supply chain by optimizing episode and point-of-care performance, freeing up capital and clinical resources, and managing contracts to optimize financial performance. A FORTUNE 500 company, Owens & Minor was founded in 1882 in Richmond, Virginia, where it remains headquartered today. The Company has distribution, production, customer service and sales facilities located across the Asia Pacific region, Europe, Latin America, and North America. For more information about Owens & Minor, visit owens-minor.com, follow @Owens_Minor on Twitter, and connect on LinkedIn at www.linkedin.com/company/owens-&-minor.

Chandrika Nigam, Director, Investor Relations, [email protected], 833-621-7812

 

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Medical Devices Supply Chain Management Health Retail Medical Supplies

MEDIA:

Logo
Logo

Shake Shack to Participate in January Virtual Investor Conferences

Shake Shack to Participate in January Virtual Investor Conferences

NEW YORK–(BUSINESS WIRE)–
Shake Shack Inc. (“Shake Shack” or the “Company”) (NYSE: SHAK), today announced that the Company will participate in the following virtual investor conferences in January:

  • On Tuesday, January 12, 2021, the Company will be presenting at the 23rd Annual ICR Virtual Conference. The presentation will begin at 8:30 a.m. ET.
  • On Tuesday, January 19, 2021, the Company will be hosting a fireside chat at the Jefferies 10th Annual Winter Restaurant, Foodservice, Gaming, Lodging & Leisure Virtual Summit.

The presentation and fireside chat will be webcast live from the Company’s Investor Relations website at http://investor.shakeshack.com.

About Shake Shack

Shake Shack is a modern day “roadside” burger stand known for its 100% all-natural Angus beef burgers, chicken sandwiches and flat-top Vienna beef dogs (no hormones or antibiotics – ever), spun-fresh frozen custard, crinkle cut fries, craft beer and wine and more. With its fresh, simple, high-quality food at a great value, Shake Shack is a fun and lively community gathering place with widespread appeal. Shake Shack’s mission is to Stand for Something Good®, from its premium ingredients and caring hiring practices to its inspiring designs and deep community investment. Since the original Shack opened in 2004 in NYC’s Madison Square Park, the company has expanded to approximately 300 locations in 30 U.S. States and the District of Columbia, including more than 120 international locations including London, Hong Kong, Shanghai, Singapore, Philippines, Mexico, Istanbul, Dubai, Tokyo, Moscow, Seoul and more.

Media:

Kristyn Clark, Shake Shack

(646) 747-8776

[email protected]

Investor Relations:

Melissa Calandruccio, ICR

Michelle Michalski, ICR

(844) SHACK-04 (844-742-2504)

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Retail Restaurant/Bar Food/Beverage

MEDIA:

Logo
Logo

SpartanNash to Present at the 2021 ICR Conference

SpartanNash to Present at the 2021 ICR Conference

GRAND RAPIDS, Mich.–(BUSINESS WIRE)–
SpartanNash Company (the “Company”) (Nasdaq: SPTN) today announced that Mark Shamber, Chief Financial Officer and Executive Vice President, will present at the 2021 ICR Conference on Tuesday, January 12, 2021 at 12:30 pm ET.

The audio portion of the virtual presentation will be webcast live over the internet hosted at SpartanNash’s website at www.spartannash.com/webcasts under the “Investor Relations” section and will remain available for replay on the Company’s website for approximately ten days.

About SpartanNash

SpartanNash (Nasdaq: SPTN) is a Fortune 400 company whose core businesses include distributing grocery products to a diverse group of independent and chain retailers, its corporate-owned retail stores and U.S. military commissaries and exchanges; as well as operating a premier fresh produce distribution network. SpartanNash serves customer locations in all 50 states and the District of Columbia, Europe, Cuba, Puerto Rico, Honduras, Bahrain, Djibouti and Egypt. SpartanNash currently operates 156 supermarkets, primarily under the banners of Family Fare, Martin’s Super Markets, D&W Fresh Market, VG’s Grocery and Dan’s Supermarket. Through its MDV military division, SpartanNash is a leading distributor of grocery products to U.S. military commissaries.

Investor Contacts:

Mark Shamber

Chief Financial Officer and Executive Vice President

(616) 878-8023

Chris Mandeville

Managing Director, ICR

(203) 682-8304

Media Contact:

Meredith Gremel

Vice President Corporate Affairs and Communications

(616) 878-2830

KEYWORDS: United States North America Michigan

INDUSTRY KEYWORDS: Retail Supermarket Food/Beverage

MEDIA:

CarLotz, Inc. Announces Participation in the 2021 ICR Conference

CarLotz, Inc. Announces Participation in the 2021 ICR Conference

RICHMOND, Va.–(BUSINESS WIRE)–
CarLotz, Inc. (“CarLotz” or the “Company”), a leading consignment-to-retail used vehicle marketplace, which recently announced it would become a public company via a merger with special purpose acquisition company Acamar Partners Acquisition Corp. (“Acamar Partners”) (Nasdaq: ACAM), today announced that the Company is scheduled to present at the 2021 ICR Conference held virtually on Wednesday, January 13, 2021, at 11:30 am Eastern Time. The Company will be represented at the conference by Michael Bor, Co-Founder and Chief Executive Officer of CarLotz.

The presentation will be webcast live over the Internet and can be accessed at www.acamarpartners.com and www.carlotz.com, under “Investors,” or by using the following link: https://www.carlotz.com/about-us/investors/. For those unable to participate during the live webcast, a replay will be available at www.acamarpartners.com and www.carlotz.com.

About CarLotz, Inc.

CarLotz is a used vehicle consignment and Retail Remarketing™ business that provides our corporate vehicle sourcing partners and retail sellers of used vehicles with the ability to access the previously unavailable retail sales channel, while simultaneously providing buyers with prices that are, on average, below those of traditional dealerships. Our mission is to create the world’s greatest vehicle buying and selling experience. We operate a technology-enabled buying, sourcing and selling model that offers a seamless omni-channel experience and comprehensive selection of vehicles, while allowing for a fully contactless end-to-end e-commerce interface that enables no hassle buying and selling. Our proprietary Retail Remarketing™ technology provides our corporate vehicle sourcing partners with real-time performance metrics and data analytics, along with custom business intelligence reporting that enables price and vehicle triage optimization between the wholesale and retail channel. Through our marketplace model, we generate significant value for both sellers and buyers through price, selection and experience. For more information, visit www.carlotz.com.

About Acamar Partners Acquisition Corp.

Acamar Partners Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Acamar Partners Acquisition Corp. raised $305.6 million in its initial public offering in February 2019 (and subsequent exercise of the underwriters’ over-allotment option). The company’s securities are quoted on Nasdaq under the ticker symbols ACAM, ACAMW and ACAMU. For more information, visit www.acamarpartners.com.

Important Additional Information and Where to Find It

This communication is being made in respect of the proposed merger transaction involving Acamar Partners and CarLotz. Acamar Partners has filed a registration statement on Form S-4 with the Securities and Exchange Commission (the “SEC”), which includes a proxy statement of Acamar Partners, a prospectus of Acamar Partners and a consent solicitation statement of CarLotz. A definitive proxy statement/prospectus/consent solicitation statement has been sent to the stockholders of Acamar Partners and CarLotz, as of the respective record dates with respect to the required stockholder approvals. Before making any voting or investment decision, investors and security holders of Acamar Partners and CarLotz are urged to carefully read the entire registration statement and proxy statement/prospectus/consent solicitation statement and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, because these documents contain important information about the proposed transaction. The documents filed by Acamar Partners with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov. In addition, the documents filed by Acamar Partners may be obtained free of charge from Acamar Partners at www.acamarpartners.com. Alternatively, these documents, when available, can be obtained free of charge from Acamar Partners upon written request to Acamar Partners Acquisition Corp., 1450 Brickell Avenue, Suite 2130, Miami, Florida 33131, or by calling 786-264-6680.

Participants in the Solicitation

Acamar Partners, CarLotz and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Acamar Partners in connection with the proposed merger. Information regarding Acamar Partners’ directors and executive officers is contained in Acamar Partners’ Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 27, 2020, and subsequent Form 8-K filed with the SEC on July 14, 2020, both of which are available at the SEC website at www.sec.gov.

Additional information regarding the interests of these participants and other persons who may be deemed to be participants in the solicitation may be obtained by reading the registration statement and the proxy statement/prospectus/consent solicitation statement and other relevant documents filed with the SEC. Free copies of these documents may be obtained as described in the preceding paragraph.

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Generally, forward-looking statements include statements that are not historical facts, such as statements concerning possible or assumed future actions, business strategies, events or results of operations, including statements regarding Acamar Partners’ and CarLotz’ expectations or predictions of future financial or business performance or conditions. Forward-looking statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates” or “intends” or similar expressions.

Forward-looking statements involve risks and uncertainties that may cause actual events, results or performance to differ materially from those indicated by such statements. Certain of these risks are identified and discussed in Acamar Partners’ Form 10-K for the year ended December 31, 2019 under “Risk Factors” in Part I, Item 1A and in Acamar Partners’ Form 10-Q for the quarterly period ended March 31, 2020, Form 10-Q for the quarterly period ended June 30, 2020 and Form 10-Q for the quarterly period ended September 30, 2020 under “Risk Factors” in Part II, Item 1A. These risk factors will be important to consider in determining future results and should be reviewed in their entirety.

In addition to risks previously disclosed in Acamar Partners’ reports filed with the SEC and those identified elsewhere in this communication, the following factors, among others, could cause actual results to differ materially from forward-looking statements or historical performance: ability to meet the closing conditions to the merger, including approval by stockholders of Acamar Partners on the expected terms and schedule; delay in closing the merger; failure to realize the benefits expected from the proposed transaction; the effects of pending and future legislation; risks related to management’s focus on the proposed transaction rather than on the ongoing business operations of CarLotz; business disruption following the transaction; risks related to Acamar Partners’ or CarLotz’ indebtedness; other consequences associated with mergers, acquisitions and legislative and regulatory actions and reforms; risks of the automotive and used vehicle industries; the potential impact of COVID-19 on the used vehicle industry and on the CarLotz business; litigation, complaints, product liability claims or adverse publicity; the impact of changes in consumer spending patterns, consumer preferences, local, regional and national economic conditions, crime, weather, demographic trends and employee availability; new entrants in the consignment-to-retail used vehicle business; technological disruptions, privacy or data breaches, the loss of data or cyberattacks; and the ability to compete successfully with new and existing market participants.

Any financial projections in this communication are forward-looking statements that are based on assumptions that are inherently subject to significant uncertainties and contingencies, many of which are beyond Acamar Partners’ and CarLotz’ control. While all projections are necessarily speculative, Acamar Partners and CarLotz believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection extends from the date of preparation. The assumptions and estimates underlying the projected results are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the projections. The inclusion of projections in this communication should not be regarded as an indication that Acamar Partners and CarLotz, or their representatives, considered or consider the projections to be a reliable prediction of future events.

Forward-looking statements speak only as of the date they are made, and Acamar Partners and CarLotz are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Readers should carefully review the statements set forth in the reports that Acamar Partners has filed or will file from time to time with the SEC. Forward-looking statements are expressed in good faith, and Acamar Partners and CarLotz believe there is a reasonable basis for them. However, there can be no assurance that the events, results or trends identified in these forward-looking statements will occur or be achieved.

Annualized, pro forma, projected and estimated numbers are used for illustrative purpose only, are not forecasts and may not reflect actual results.

This communication is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in Acamar Partners and is not intended to form the basis of an investment decision in Acamar Partners. All subsequent written and oral forward-looking statements concerning Acamar Partners and CarLotz, the proposed transaction or other matters and attributable to Acamar Partners and CarLotz or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above.

Investor Contact:

[email protected]

Media:

[email protected]

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Retail Automotive General Automotive Other Automotive Other Retail Specialty

MEDIA:

Logo
Logo

Nutanix to Present at Upcoming Investor Conference

Nutanix to Present at Upcoming Investor Conference

SAN JOSE, Calif.–(BUSINESS WIRE)–Nutanix (NASDAQ: NTNX), a leader in private cloud, hybrid and multicloud computing, today announced that its management will present at the following upcoming financial community event:

Needham 23rd Annual Virtual Growth Conference

Monday, January 11, 2021

11:00 a.m. PT; 2:00 p.m. ET

A live webcast and replay of the presentation will be accessible on the Nutanix Investor Relations website at ir.nutanix.com.

About Nutanix

Nutanix is a global leader in cloud software and a pioneer in hyperconverged infrastructure solutions, making computing invisible anywhere. Organizations around the world use Nutanix software to leverage a single platform to manage any app at any location at any scale for their private, hybrid and multicloud environments. Learn more at www.nutanix.com or follow us on Twitter @nutanix.

© 2021 Nutanix, Inc. All rights reserved. Nutanix, the Nutanix logo, and all Nutanix product and service names mentioned herein are registered trademarks or trademarks of Nutanix, Inc. in the United States and other countries. All other brand names mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s). This release may contain links to external websites that are not part of Nutanix.com. Nutanix does not control these sites and disclaims all responsibility for the content or accuracy of any external site. Our decision to link to an external site should not be considered an endorsement of any content on such a site.

Investor Contact

Shane Xie

(510) 543-1443

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Technology Other Technology Software Networks Internet

MEDIA:

Domo Executives to Participate in Needham Virtual Growth Conference as well as Jefferies Virtual Software Bus Tour

Domo Executives to Participate in Needham Virtual Growth Conference as well as Jefferies Virtual Software Bus Tour

SILICON SLOPES, Utah–(BUSINESS WIRE)–Domo (Nasdaq: DOMO), provider of the Domo Business Cloud, today announced management will present at both the 23rd Annual Needham Virtual Growth Conference on Wednesday, January 13, 2021 at 12:30pm ET, and at the Jefferies Virtual Software Bus Tour on Thursday, January 14, 2021 at 5:00pm ET.

A live webcast of Domo’s presentations at each event will be available on the Domo Investor Relations website at http://www.domo.com/IR.

About Domo

Domo is the Business Cloud, empowering organizations of all sizes with BI leverage at cloud scale, in record time. With Domo, BI-critical processes that took weeks, months or more can now be done on-the-fly, in minutes or seconds, at unbelievable scale. For more information about how Domo (Nasdaq: DOMO) helps its customers go fast, go big and go bold, visit www.domo.com. You can also follow Domo on Twitter, Facebook and LinkedIn.

Domo, Domo Business Cloud and Domo is the Business Cloud are registered trademarks of Domo, Inc.

Domo Disclosure Channels to Disseminate Information

Domo investors and others should note that we announce material information to the public about our company, products and services, and other issues through a variety of means, including Domo’s website, press releases, SEC filings, blogs and social media, in order to achieve broad, non-exclusionary distribution of information to the public. We intend to use the Domo Facebook page, the Domo LinkedIn page, the Domo blog, the @Domotalk Twitter account and the @JoshJames Twitter account as a means of disclosing information about the Company and its services and for complying with the disclosure obligations under Regulation FD. The information we post through these social media channels may be deemed material. Accordingly, we encourage investors and others to monitor these social media channels in addition to following our press releases, SEC filings and public conference calls and webcasts. The social media channels that we intend to use as a means of disclosing the information described here may be updated from time to time as listed on our investor relations webpage.

Media –

Julie Kehoe

[email protected]

Investors –

Peter Lowry

[email protected]

KEYWORDS: Utah United States North America

INDUSTRY KEYWORDS: Software Technology Internet Data Management

MEDIA:

Logo
Logo

Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect Conference

PR Newswire

RED BANK, N.J., Jan. 6, 2021 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the H.C. Wainwright BioConnect 2021 Conference, being held virtually January 11-14, 2021.

A replay of the pre-recorded fireside chat will be available beginning Monday, January 11, at 6:00 am E.T. and can be accessed by visiting the Events and Webcasts section of the Company’s website: http://investors.proventionbio.com/events. The webcast will be archived on the Company’s website for 30 days following the presentation.

About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company has submitted a Biologics License Application (BLA) to the FDA for its lead investigational drug candidate, teplizumab, for the delay or prevention of clinical type 1 diabetes in at-risk individuals. The Company’s pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the Company’s website in the “News” section. Accordingly, investors should monitor this portion of the Company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contact:

Sam Martin, Argot Partners
[email protected]
212-600-1902

Media Contact:

Lori Rosen, LDR Communications
[email protected]
917-553-6808

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-participate-in-the-hc-wainwright-virtual-bioconnect-conference-301202297.html

SOURCE Provention Bio, Inc.

Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

PR Newswire

EMERYVILLE, Calif., Jan. 6, 2021 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect 2021 Conference being held January 11-14, 2021.

The on demand presentation will be available, beginning Monday, January 11, 2021 at 6:00 a.m. E.T. and may be accessed through the “Events & Presentations” page on the “Investors” section of the Company’s website at http://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:

Nicole Arndt

[email protected]

510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-virtual-bioconnect-2021-conference-301202218.html

SOURCE Dynavax Technologies

Viking Therapeutics Announces Senior Management Team Appointments

Greg Zante Promoted to Chief Financial Officer and Marianne Mancini Promoted to Chief Operating Officer

PR Newswire

SAN DIEGO, Jan. 6, 2021 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced two key executive promotions. The company has named Greg Zante as chief financial officer and Marianne Mancini as chief operating officer. 

Mr. Zante possesses nearly 25 years of financial management experience at public and private companies in the biotechnology and accounting industries and most recently served as Viking’s senior vice president of finance. Ms. Mancini has more than 30 years of experience in the pharmaceutical and biotechnology industry focusing on the management and oversight of clinical trials from early-stage to late-stage drug development and most recently served as the company’s senior vice president of clinical operations.

“Greg and Marianne have played integral roles in the successes that Viking has achieved over the past several years, including the advancement of our pipeline of best-in-class therapies for metabolic and endocrine disorders and the execution of a prudent financial strategy to support our continued progress,” stated Brian Lian, Ph.D., chief executive officer of Viking.  “These promotions are well deserved and reflect Greg’s and Marianne’s contributions to Viking’s position as a leader in the discovery and development of novel therapies for the treatment of non-alcoholic steatohepatitis or NASH.”

Prior to joining Viking in 2016 as vice president of finance and operations, Mr. Zante was chief financial officer at Dance Biopharm, a diabetes-focused biopharmaceutical company, where he managed the company’s private financing strategy and positioned it for initial public offering activities. Mr. Zante has also previously held senior positions at several biopharmaceutical companies including Sangamo Therapeutics, Calyx Therapeutics and Matrix Pharmaceuticals. He is a certified public accountant in the state of California and previously served as a senior staff accountant at Ernst & Young. Mr. Zante received his bachelor’s degree in business-economics from the University of California, Los Angeles.

Prior to joining Viking in 2015 as vice president of clinical operations, Ms. Mancini was senior director of clinical operations at Ambit Biosciences Corporation, a company focused on the development of oncology therapies for the treatment of acute myeloid leukemia. Previously, she was the senior director of clinical operations at Aires Pharmaceuticals, Inc., a company focused on developing therapies for pulmonary vascular disorders, and also served as senior director of project management and clinical operations at Arena Pharmaceuticals, Inc., where she was the project team leader for the company’s lead obesity compound, BELVIQ®. Ms. Mancini has also previously held positions at Baxter BioSciences, Genentech and Procter & Gamble Pharmaceuticals. She holds a master’s degree in bioethics from Loyola Marymount University, an MBA from the University of Phoenix, and a bachelor’s degree in nutritional sciences from McGill University.

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.  Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives.  The company’s clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.  In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.  The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial.  The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-announces-senior-management-team-appointments-301202233.html

SOURCE Viking Therapeutics, Inc.